Hints and tips:
Related Special Reports
Related Topics
...Late last year, AstraZeneca agreed to buy its first vaccine company, Icosovax, in a deal worth up to $1.1bn....
...Shares in GSK have fallen 5 per cent in the past five years, while many of its European rivals including Novo Nordisk, AstraZeneca and Novartis have soared....
...AstraZeneca has also said it is interested in doing deals with Chinese biotechs....
...Top holdings in his Jupiter UK Alpha fund, which manages £585mn, include pharmaceutical company AstraZeneca, power generation business Drax, natural resources group Glencore and Lloyds Banking Group....
...These data reinforce that message,” said Susan Galbraith, executive vice-president of oncology R&D at AstraZeneca....
...AstraZeneca’s jab developed with Oxford university was widely used across the world, but sales fell more than 99 per cent to just $12mn in 2023....
...Muir had worked at AstraZeneca, which has more than 8,700 employees in the UK, since 1998....
...In August, AstraZeneca signed a deal with China’s CanSino Biologics for the production of its potential mRNA vaccines....
...The deal is expected to close in the first quarter of next year, AstraZeneca said....
...AstraZeneca updated the label to warn recipients of the concern on April 7 and April 15....
...The agreement is part of AstraZeneca’s ambitious plans to replace traditional chemotherapy with a new generation of targeted drugs....
...Galbraith did not comment on whether AstraZeneca had bid to partner on the next drugs in the pipeline....
...Shares in AstraZeneca climbed 3 per cent on Thursday, having lost 9.2 per cent in the year to date period....
...AstraZeneca shares are down about 4.5 per cent in the year so far....
...crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the UK’s AstraZeneca...
...AstraZeneca chair sees past vaccine headwinds Michel Demaré, non-executive chair of the AstraZeneca board, appears bullish about the company’s prospects....
...a bid to gain good publicity for its penguins, the company has named them after public figures, including tennis player Emma Raducanu, diver Tom Daley and Dame Sarah Gilbert, who led development of the AstraZeneca...
...AstraZeneca bought a rare disease business when it acquired Alexion in a $39bn deal in 2020....
...Shares in AstraZeneca rose 4 per cent to £111.54 in morning trading in London....
...The £64bn company has long lagged behind £168bn Anglo-Swedish rival AstraZeneca, with investors raising questions over GSK’s pipeline of products and its growth plans....
...AstraZeneca said at the time it did “not comment on rumours or speculations around future strategy or M&A”....
...Shares in AstraZeneca were down 5 per cent to £107.41 in early trading in London....
...As tensions heighten between the US and China, AstraZeneca may offer its own twist by carving out its Chinese business....
...While rival AstraZeneca’s share price has soared almost 90 per cent over the past 5 years, GSK’s stands only 3 per cent higher....
...AstraZeneca declined to comment on Wang’s statement....
International Edition